We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

Rank Sector Weight
1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMEA icon
176
CALL
Biomea Fusion
BMEA
$92.5M
$2.34K ﹤0.01%
+1,138
New +$2.19K
RVMD icon
177
CALL
Revolution Medicines
RVMD
$39.6B
$2.05K ﹤0.01%
+461
New +$17.7K
LLY icon
178
CALL
Eli Lilly
LLY
$1.05T
$1.57K ﹤0.01%
23
– –
INSM icon
179
Insmed
INSM
$23.5B
$805 ﹤0.01%
+8
New +$612
ALNY icon
180
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-3,034
Closed -$819K
ALNY icon
181
PUT
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-46
Closed -$43K
AMGN icon
182
CALL
Amgen
AMGN
$198B
– –
-239
Closed -$618K
ANAB icon
183
CALL
AnaptysBio
ANAB
$1.72B
– –
-236
Closed -$9
ANAB icon
184
PUT
AnaptysBio
ANAB
$1.72B
– –
-303
Closed -$2.12K
ASND icon
185
Ascendis Pharma A/S
ASND
$17.1B
– –
-1,906
Closed -$297K
BMEA icon
186
PUT
Biomea Fusion
BMEA
$92.5M
– –
-406
Closed -$126K
CADL icon
187
Candel Therapeutics
CADL
$746M
– –
-5,918
Closed -$33.4K
CAPR icon
188
CALL
Capricor Therapeutics
CAPR
$1.13B
– –
-70
Closed -$525
CLOV icon
189
Clover Health Investments
CLOV
$2.43B
– –
-45,276
Closed -$163K
CMA
190
DELISTED
Comerica
CMA
– –
-11,964
Closed -$707K
CMPX icon
191
CALL
Compass Therapeutics
CMPX
$369M
– –
-459
Closed -$13.1K
CNC icon
192
Centene
CNC
$32.8B
– –
-168,883
Closed -$10.3M
CNTA
193
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-37,720
Closed -$542K
COOP
194
DELISTED
Mr. Cooper
COOP
– –
-2,388
Closed -$286K
CORT icon
195
CALL
Corcept Therapeutics
CORT
$9.72B
– –
-92
Closed -$414K
CVS icon
196
CVS Health
CVS
$137B
– –
-34,159
Closed -$2.31M
CYTK icon
197
Cytokinetics
CYTK
$10.9B
– –
-4,576
Closed -$184K
DVA icon
198
DaVita
DVA
$15.2B
– –
-10,722
Closed -$1.64M
EOLS icon
199
PUT
Evolus
EOLS
$377M
– –
-115
Closed -$10.6K
EWTX icon
200
CALL
Edgewise Therapeutics
EWTX
$4.28B
– –
-226
Closed -$75K
6 7
8
9 10

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.